Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Pazopanib
Multitargeted tyrosine kinase inhibitor (anti-angiogenic) · Antineoplastic
START
800 mg PO once daily, fasting
TYPICAL MAX
800 mg/day (200 mg if moderate hepatic impairment)
STOP IF
ALT >3× ULN with bilirubin, QTc >500 ms, or perforation/bleed
WATCH
LFTs (baseline + serial), BP, ECG/electrolytes, thrombosis/bleeding
CDSCO approvedATC L01EX03
KDIGO 2024 + manufacturer label
- ONSET
- 2h · absorption
- PEAK
- 3h · Tmax
- t½
- 1.3d · t½
- DURATION
- 1d · once-daily
EXCRETION
Mainly faecal; <4% renal
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Can cause fetal harm — avoid; effective contraception required.
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- AmiodaroneSevereDatabaseDDInter
- AmisulprideSevereDatabaseDDInter
- AmprenavirSevereDatabaseDDInter
Mechanism
Inhibits VEGFR-1/2/3, PDGFR-alpha/beta and c-KIT tyrosine kinases, blocking tumour angiogenesis and proliferation.
Indications
Advanced renal cell carcinomaAdvanced soft-tissue sarcoma (selected, after chemotherapy)
Dosing
- Adult
- 800 mg PO once daily, without food (≥1 h before or 2 h after); reduce in steps (e.g., 600, 400 mg) for toxicity/hepatic impairment.
- Pediatric
- Not established.
- Renal adjustment
- No adjustment for CrCl >30; limited data <30.
- Hepatic adjustment
- Moderate impairment: 200 mg once daily. Severe: avoid (contraindicated).
- Geriatric
- No specific adjustment; monitor toxicity.
- Max dose
- 800 mg/day
Pharmacokinetics
Onset
Antitumour effect over weeks
Peak effect
~2–4 h (Tmax)
Duration
~24 h (once-daily)
Half-life
~31 h
Bioavailability
Variable; increased and more variable with food
Protein binding
>99%
Metabolism
Hepatic CYP3A4 (minor 1A2/2C8)
Excretion
Mainly faecal; <4% renal
Contraindications
- Severe hepatic impairment
- Hypersensitivity
- Caution: QT prolongation, recent haemorrhage/arterial thrombosis, GI perforation risk
Side effects
Common
HypertensionDiarrhoeaHair colour changeNauseaFatigueAnorexia
Serious
- Hepatotoxicity (boxed — fatal cases)
- QT prolongation / torsades
- Arterial/venous thromboembolism
- Haemorrhage
- GI perforation/fistula
- Posterior reversible encephalopathy
Pregnancy & lactation
Pregnancy
Can cause fetal harm — avoid; effective contraception required.
Lactation
Discontinue breastfeeding during therapy.
Drug interactions
Amiodarone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amisulpride
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Arsenic Trioxide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Azithromycin
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Bedaquiline
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Benzhydrocodone
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Bepridil
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Ask House about Pazopanib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e, Katzung, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20